GLP-1 Receptor Agonist Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07627191

Title field or adapter rule

{'original_value': 'GLP-1 Receptor Agonist Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:25.428714+00:00

Published At

2026-09-18T00:00:00+00:00

Record Updated At

2026-09-18

Source Retrieved At

2026-10-31T22:17:56.788771+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pancreatic Cancer", "Colorectal Cancer", "Hepatocellular Carcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-18", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07627191"

protocolSection.identificationModule.officialTitle

"GLP-1 Receptor Agonist Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["EARLY_PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Pancreatic Cancer (protocolSection.conditionsModule.conditions)
• Colorectal Cancer (protocolSection.conditionsModule.conditions)
• Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Metastatic Colorectal Adenocarcinoma (CRC)', 'Metastatic Hepatocellular Carcinoma (HCC)', 'Metastatic Pancreatic Adenocarcinoma (PDAC)'], 'description': 'Patients will receive 6 months of weekly semaglutide; weekly subcutaneous injection; dose escalation will occur every 4 weeks with dose titration as follows: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → Maintenance at 2.4 mg or 1.7 mg pending tolerability.', 'name': 'GLP1-RA (semaglutide)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• GLP1-RA (semaglutide) (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.